<DOC>
	<DOCNO>NCT00009204</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo-controlled , fix dose study currently conduct two geropsychiatric unit Western Psychiatric Institute Clinic . It seek evaluate short-term safety efficacy citalopram perphenazine treatment 112 patient suffer behavioral disturbance associate dementia . Findings research may directly lead improve acute pharmacotherapy psychosis behavioral problem patient diagnose dementia . Improved treatment behavioral complication reduce side effect would reduce excess disability patient diagnose dementia , allow maintain community great period time .</brief_summary>
	<brief_title>Serotonergic Pharmacotherapy Agitation Dementia</brief_title>
	<detailed_description>The principal investigator conduct inpatient study Western Psychiatric Institute Clinic involve two medication treatment emotional behavioral disturbance may accompany dementia . In study , 112 patient enrol 17 day order investigate safety effectiveness medication . Forty-two patient give recently FDA-approved antidepressant medication call citalopram 42 receive one current , usual antipsychotic medication call perphenazine . An additional 28 patient give non-active placebo capsule . Which treatment patient give study determine chance . Findings investigation may directly lead improvement symptom : agitation , hostility , suspiciousness , hallucination , unusual thought . Improved treatment problematic behavior decrease medication-associated side effect would enable dementia patient care home environment longer period time .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Perphenazine</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<criteria>Meets DSMIV criterion diagnosis dementia Alzheimer 's type ( AD ) , Vascular dementia ( VD ) , mixed ( AD VD ) dementia NOS ( Not Otherwise Specified ) Presents psychosis behavioral problem severe enough endanger patient 's health , wellbeing safety , evidence score least 3 ( moderate ) one Neurobehavioral Rating Scale ( NBRS ) agitation item ( 8,11,14 ) psychosis item ( 16,18,20 ) secondary physical illness amenable environmental optimization Able participate study evaluation ingest oral medication Has next kin guardian available consent patient 's participation . Has unstable medical illness include significant cardiac ( specifically bradycardia ventricular rate 50 ) , renal , hepatic , neurological illness ( especially Parkinson 's disease ) dementia Meets DSMIV criterion Delirium upon admission Western Psychiatric Institute Clinic Has medicate within 4 week protocol admission fluoxetine 2 week monoamine oxidase inhibitor ( patient undergo monitor psychotropic drug washout prior enter protocol ) Is currently treat cognitive enhance drug ( Tacrine Aricept ) experimental drug Has concurrent diagnosis schizophrenia , bipolar disorder , major depression Has preexisting orthostatic hypotension ( &gt; 20 mmHg change sit stand pressure )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Behavioral problem</keyword>
	<keyword>Agitation</keyword>
</DOC>